ArticleTrends in immunology2021
'(m
Article in Trends in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- RNA mActa pharmacologica Sinica · 2026Review
- Regulatory role and subtype analysis of m6A modifications in dermatomyositis.Global medical genetics · 2026Article
- Deciphering the molecular landscape of NMDAR-E associated ovarian teratomas: a Multi-Omics approach.Journal of ovarian research · 2025Article
- METTL3: a multifunctional regulator in diseases.Molecular and cellular biochemistry · 2025Review
- Mechanism of N6-Methyladenosine Modification in the Pathogenesis of Depression.Molecular neurobiology · 2025Review
- N6-methyladenosine (m6A) modification in inflammation: a bibliometric analysis and literature review.PeerJ · 2024Review
- Post-transcriptional checkpoints in autoimmunity.Nature reviews. Rheumatology · 2023Review
- The RNA-binding protein IMP2 drives a stromal-Th17 cell circuit in autoimmune neuroinflammation.JCI insight · 2022Article
- m6A Methylation in Cardiovascular Diseases: From Mechanisms to Therapeutic Potential.Frontiers in genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Covalent RNA modifications that regulate gene expression post transcriptionally, in particular N6-methyladenosine (m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.